Cidara expands Phase 3 trial of CD388, accelerates enrollment start to September 2025

Cidara Therapeutics, Inc.

Study population expanded to adults 65+ and those 12+ with comorbidities; eligible US population rises from ~50M to >100M.
Phase 3 study to evaluate single 450-mg subcutaneous dose of CD388 vs placebo, targeting 6,000 subjects.
Enrollment to begin by end of September 2025 in Northern Hemisphere, with continuation to Southern Hemisphere spring 2026.
Interim analysis planned after Northern Hemisphere flu season; existing cash expected to fully fund program through completion.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.